Selank vs Semax

Selank and Semax are often mentioned together because they share a delivery platform (intranasal spray), a molecular size (both seven amino acids), and a research origin (both developed at the Institute of Molecular Genetics, Russian Academy of Sciences). But their biological targets are as different as anxiolytics and nootropics—because that's exactly what they are.

Selank is a synthetic analog of tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) that modulates immune function. Selank extends tuftsin to seven amino acids and adds a Pro-Gly-Pro C-terminal tail that stabilizes the molecule. Its primary mechanism involves enkephalinase inhibition—blocking the enzyme that degrades endogenous opioid peptides—alongside direct modulation of IL-6 and TNF-alpha cytokine expression and GABAergic system interaction [PMID: 21833148]. The net effect is anxiolytic: reducing anxiety without the sedation, tolerance, or dependence profile of benzodiazepines.

Semax derives from a different peptide entirely: adrenocorticotropic hormone (ACTH). Specifically, it is a synthetic analog of ACTH(4-10) with a Pro-Gly-Pro-NH2 C-terminal modification for stability. Its primary mechanism is BDNF (brain-derived neurotrophic factor) expression enhancement in the hippocampus and cortex, with downstream activation of TrkB receptors promoting neuroplasticity [PMID: 21833148]. Semax also modulates serotonin and dopamine neurotransmitter systems [PMID: 25313017]. The net effect is nootropic: enhancing cognitive function, memory consolidation, and neuroprotection.

Both have completed clinical studies in Russia and are approved for clinical use there. Both are administered as intranasal sprays, bypassing the blood-brain barrier through the olfactory and trigeminal nerve pathways. But the question for researchers is not which is 'better'—it's whether you're targeting anxiety or cognition, because these two peptides operate in different neurological domains.

Selank's primary mechanism centers on endogenous opioid modulation. By inhibiting enkephalinases—the enzymes (particularly neprilysin and aminopeptidase N) that degrade enkephalins and other endogenous opioid peptides—Selank increases the availability of these natural anxiolytic molecules in synaptic spaces [PMID: 21833148]. This is a modulatory rather than agonist approach: Selank doesn't directly activate opioid receptors (like morphine does), but rather enhances the body's own opioid tone by preventing premature degradation.

Simultaneously, Selank modulates cytokine expression in the central nervous system. In preclinical studies, it reduced IL-6 and TNF-alpha levels in brain tissue, attenuating neuroinflammation [PMID: 21493795]. This anti-neuroinflammatory action is increasingly recognized as relevant to anxiety disorders, as chronic low-grade neuroinflammation is associated with HPA axis dysregulation and anxiety phenotypes.

Selank also interacts with the GABAergic system—the same neurotransmitter system targeted by benzodiazepines, but through a different mechanism. Rather than directly potentiating GABA-A receptor function (as benzodiazepines do), Selank appears to modulate GABAergic tone indirectly, producing anxiolytic effects with less sedation and without the tolerance development characteristic of direct GABA-A agonists [PMID: 21833148].

Semax operates in a completely different neurological domain. Its primary target is the brain-derived neurotrophic factor (BDNF) system. In rodent studies, intranasal Semax increased BDNF mRNA expression in the hippocampus and frontal cortex within hours of administration [PMID: 21833148]. BDNF is a critical mediator of neuroplasticity—it promotes synaptic strengthening (long-term potentiation), dendritic branching, and neuronal survival through activation of the TrkB (tropomyosin receptor kinase B) receptor.

Semax also modulates monoaminergic neurotransmitter systems. It increases serotonin and dopamine turnover in the brain [PMID: 25313017], which contributes to its mood-modulating and pro-cognitive effects. The serotonergic modulation may explain Semax's reported mood-stabilizing properties, while dopaminergic effects likely contribute to its attentional and motivational benefits.

The mechanistic distinction maps directly to application: Selank enhances inhibitory (GABAergic/opioidergic) tone to reduce neural excitability and anxiety. Semax enhances excitatory/plasticity-promoting (BDNF/monoaminergic) signaling to improve cognitive function and neural resilience. They are not interchangeable—they are tools for different neurological objectives.

Selank and Semax share a remarkable structural and practical similarity despite their different mechanisms. Both are seven-amino-acid synthetic peptides (heptapeptides) with Pro-Gly-Pro C-terminal modifications that confer resistance to enzymatic degradation. Both were developed at the same research institute (Institute of Molecular Genetics, Russian Academy of Sciences) and both have completed human clinical studies in Russia.

Both are administered intranasally, bypassing the blood-brain barrier through the olfactory nerve pathway and trigeminal nerve connections to the brain. This delivery route is a significant shared advantage: it avoids first-pass hepatic metabolism, produces rapid CNS onset (within 15–30 minutes), and is non-invasive compared to subcutaneous injection.

Both are approved for clinical use in Russia (Selank for generalized anxiety disorder; Semax for cognitive impairment and optic nerve conditions) and both have published human pharmacokinetic and efficacy data. Both have short plasma half-lives (minutes) but produce CNS effects that outlast their circulating presence, suggesting they trigger downstream signaling cascades rather than acting as simple occupancy-based drugs.

Both share a favorable safety profile in published clinical data: no serious adverse events, no documented dependence or tolerance, and no significant withdrawal effects. This distinguishes them from the benzodiazepines (Selank's functional competitors) and established nootropics like modafinil (Semax's functional competitors).

The primary mechanistic axis is the fundamental difference. Selank operates through inhibitory neuromodulation: opioidergic (enkephalinase inhibition), GABAergic, and anti-neuroinflammatory pathways. Semax operates through plasticity-enhancing and excitatory neuromodulation: BDNF-TrkB signaling, serotonergic, and dopaminergic pathways. These are not variations on a theme—they are different neurological systems.

Clinical indication follows the mechanism. Selank is indicated for generalized anxiety disorder and anxiety-related conditions. In clinical trials, it produced anxiolytic effects comparable to low-dose benzodiazepines without sedation, cognitive impairment, or dependence [PMID: 21833148]. Semax is indicated for cognitive impairment, stroke recovery, and optic nerve pathology. In clinical studies, it improved attention, memory consolidation, and information processing speed [PMID: 25313017].

The neuroinflammatory angle is unique to Selank. Its ability to reduce IL-6 and TNF-alpha in CNS tissue positions it not just as an anxiolytic but as a neuroimmune modulator—relevant for research on neuroinflammation-driven mood disorders, post-infection anxiety, or HPA axis dysregulation [PMID: 21493795]. Semax lacks this cytokine-modulating mechanism.

BDNF enhancement is unique to Semax. This positions it for research on neurodegenerative conditions (Alzheimer's, Parkinson's), traumatic brain injury recovery, and age-related cognitive decline—conditions where neuroplasticity promotion is therapeutically relevant. Selank does not upregulate BDNF.

Drug interaction profiles may differ. Selank's opioidergic modulation could theoretically interact with exogenous opioid medications or other enkephalinase inhibitors. Semax's monoaminergic effects could interact with SSRIs, SNRIs, or dopaminergic medications. These interactions have not been formally studied but are mechanistically plausible.

Onset and duration of subjective effects differ anecdotally. Selank users report rapid anxiolytic onset (15–30 minutes) with effects lasting 2–4 hours. Semax users report cognitive enhancement onset within 30–60 minutes with longer duration (4–8 hours). These timelines are not from controlled pharmacokinetic studies but from consistent user reports across research communities.

Choose Selank if your research targets anxiety, stress response, or neuroinflammation. Its triple mechanism—opioidergic enhancement, GABAergic modulation, and anti-neuroinflammatory action—addresses anxiety through multiple converging pathways without the drawbacks of direct GABA-A agonism (sedation, tolerance, dependence). It is also relevant for research on immune-brain axis interactions, as its tuftsin-derived structure gives it immunomodulatory properties beyond pure anxiolysis.

Choose Semax if your research targets cognitive enhancement, neuroprotection, or neuroplasticity. Its BDNF-TrkB activation makes it relevant for models of learning and memory consolidation, neurodegenerative disease progression, traumatic brain injury recovery, and age-related cognitive decline. Its serotonergic and dopaminergic modulation also makes it relevant for attention disorders and motivation research.

For stress-related cognitive impairment (where anxiety and cognitive dysfunction co-occur), the choice depends on which mechanism you want to study. If the research question is 'does reducing neuroinflammation-driven anxiety improve cognitive performance?'—Selank is the tool. If the question is 'does enhancing BDNF-mediated neuroplasticity improve resilience to stress?'—Semax is the tool.

Can they be combined? Theoretically yes, and some researchers have explored this for stress-related conditions where both anxiety and cognitive deficits are present. There is no known pharmacological contraindication—Selank's inhibitory modulation and Semax's excitatory/plasticity promotion operate through non-competing pathways.